Codiak BioSciences (Sarepta)

Cambridge, MA
Find alternatives to Codiak BioSciences (Sarepta) for Exosome →
Hybrid — also manufactures internal programs
16 confirmed programs · 2 sponsors · Last scored 2026-10-29
60.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (16) ✓ SEC Filings (20) ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Codiak BioSciences (Sarepta)

Signal Score
60.3/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Cambridge, MA
Modalities
Exosome
Active Programs
16 confirmed from ClinicalTrials.gov across 2 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Codiak BioSciences (Sarepta)

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 60.0
16 active programs across 2 sponsors
Modalities: Exosome
8 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
16 active programs across 2 sponsors · Modalities: Exosome · 8 programs in advanced phases (Phase 2/3)
Programs 16
Sponsors2
ModalitiesExosome
16 active programs across 2 sponsors
Modalities: Exosome
8 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06952686 A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type... PHASE3 Withdrawn
NCT06747273 Study to Evaluate the Safety, Tolerability, and Efficacy of... PHASE1 Terminated
NCT06597656 A Gene Transfer Therapy to Evaluate the Safety and Efficacy... PHASE1 Terminated
NCT06270719 An Observational Study Comparing Delandistrogene Moxeparvovec... NA Enrolling By Invitation
NCT06241950 A Gene Transfer Therapy Study to Evaluate the Safety and... PHASE1 Terminated
NCT06246513 A Trial to Learn More About an Experimental Gene Therapy... PHASE3 Active Not Recruiting
NCT05881408 A Gene Transfer Therapy Study to Evaluate the Safety and... PHASE3 Active Not Recruiting
NCT05906251 A Gene Transfer Study to Evaluate the Safety, Tolerability... PHASE1 Terminated
NCT05876780 A Gene Transfer Single Dose Study to Evaluate the Safety,... PHASE1 Active Not Recruiting
NCT05096221 A Gene Transfer Therapy Study to Evaluate the Safety and... PHASE3 Completed
View all 16 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: Sarepta Therapeutics
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Parent company: Sarepta Therapeutics
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Cambridge, MA
Modalities: Exosome
Capacity assessment: 53.0/100
Sites: Cambridge, MA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Cambridge, MA
Modalities: Exosome
Capacity assessment: 53.0/100

Clinical Activity 16 studies

NCT06952686 A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric... PHASE3 Withdrawn NCT06747273 Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004... PHASE1 Terminated NCT06597656 A Gene Transfer Therapy to Evaluate the Safety and Efficacy of... PHASE1 Terminated NCT06270719 An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS)... NA Enrolling By Invitation NCT06241950 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of... PHASE1 Terminated NCT06246513 A Trial to Learn More About an Experimental Gene Therapy Called... PHASE3 Active Not Recruiting NCT05881408 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of... PHASE3 Active Not Recruiting NCT05906251 A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of... PHASE1 Terminated NCT05876780 A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and... PHASE1 Active Not Recruiting NCT05096221 A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of... PHASE3 Completed NCT04626674 A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From... PHASE1 Recruiting NCT04179409 A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS... PHASE2 Completed NCT03652259 Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for... PHASE1/PHASE2 Terminated NCT03375164 A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene... PHASE1/PHASE2 Completed NCT02710500 rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies PHASE1 Completed NCT01976091 A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004... PHASE1/PHASE2 Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (19 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the board covers the whole group and doesn't say which business unit a role belongs to. We'd rather show no number than one that isn't really this company's.
Source: sarepta.wd5.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

8-K 2026-09-23 5 keyword mentions
"REGENXBIO and UPenn released Sarepta, Catalent and their affiliates from any claims relating to any Sarepta gene therapy product that uses the AAVrh74-based capsid, including ELEVIDYS, that are claims of infringement of the ‘274 Patent, the ‘617 Patent and U.S."
"In addition, REGENXBIO and UPenn agreed not to sue Sarepta, Catalent or their current affiliates, licensees, commercial partners, successors and permitted assigns with respect to any claims of patent infringement of the UPenn Patents to the extent that infringement arises from or relates to any Sarepta gene therapy product that uses an AAVrh74-based capsid, including ELEVIDYS."
"REGENXBIO further agreed not to sue Sarepta or its licensees, commercial partners, successors and permitted assigns with respect to claims of patent infringement of any REGENXBIO-controlled or owned patents or patent applications that cover the existing form of ELEVIDYS or the AAVrh74 capsid sequence."
10-Q 2026-08-05 115 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, small interfering RNA ("siRNA") knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"The Company's gene therapy product, ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-(“AAV”) based gene therapy, was initially granted accelerated approval from the FDA in June 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene."
"In June 2025, the Company received a milestone payment of $ 63.5 million in connection with the receipt of regulatory approval of ELEVIDYS in Japan for individuals ages 3- to less than 8-years-old, who do not have any deletions in exon 8 and/or exon 9 in the Duchenne gene and who are negative for anti-AAVrh74 antibodies."
8-K 2026-08-05 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On August 5, 2026, Sarepta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K."
8-K 2026-07-27 0 keyword mentions
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026 (the “Effective Date”). Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director, to"
"Item 7.01 Regulation FD Disclosure: The Company issued a press release in connection with the announcement of Dr. Severino’s appointment as Chief Executive Officer, a copy of which is furnished herewith as Exhibit 99.1."
8-K 2026-06-04 0 keyword mentions
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers: On June 4, 2026, Sarepta Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve the Company’s 2026 Equity Incentive Plan (the “2026 Plan”). The 2026 Plan supersedes and replaces the Company’s 2018 Equity Incentive Plan, as amended. "
"Item 5.07 Submission of Matters to a Vote of Security Holders: The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal. As of the record date for the Annual Meeting, April 8, 2026, there were 105,571,146 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 82,309,288 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which repr"
10-Q 2026-05-06 110 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, small interfering RNA ("siRNA") knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"The Company's gene therapy product, ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-(“AAV”) based gene therapy, was initially granted accelerated approval from the FDA in June 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene."
"Contract manufacturing revenue and royalty revenue are included in collaboration and other revenues in the unaudited condensed consolidated statements of comprehensive income (loss)."
8-K 2026-05-06 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On May 6, 2026, Sarepta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K."
10-K 2026-03-02 138 keyword mentions
"These forward-looking statements include, but are not limited to: • our belief that our proprietary technology, technology platforms and collaborations can be used to develop potential therapeutic candidates to treat a broad range of diseases, including the diseases that we are targeting; • our expectation that our partnerships with manufacturers will support our clinical and commercial manufacturing capacity for our products and product candidates, including our posphorodiamidate morpholino oli"
"Food and Drug Administration (the “FDA") has placed on our investigational use gene therapy clinical trials for Limb-girdle muscular dystrophy ("LGMD") in July 2025 and the revocation of the platform technology designation for our AAVrh74 platform technology previously granted on June 2, 2025; • the possible impacts of the results of our ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45, including the timing and outcome of any additional results, potential regulatory actions from the FDA,"
"(“Catalent”) will support our clinical and commercial manufacturing demand for certain of our programs, while also acting as a manufacturing platform for potential future gene therapy programs; • our expectation that Aldevron LLC (“Aldevron”) will provide Good Manufacturing Processes (“GMP”)-grade plasmid for our current and any future gene therapy programs; • the possible impacts of the ELEVIDYS Suspension (as defined below); • the possible impact of regulations and regulatory decisions by the "
8-K 2026-02-25 0 keyword mentions
8-K 2026-02-25 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2025-12-19 0 keyword mentions
8-K 2025-12-11 0 keyword mentions
10-Q 2025-11-06 119 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, small interfering RNA ("siRNA") platform, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-(“AAV”) based gene therapy, was approved by the FDA in June 2024 for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene, as well as for non-ambulatory patients under the accelerated approval pathway."
"In June 2025, the Company received a milestone payment of $ 63.5 million in connection with the receipt of regulatory approval of ELEVIDYS in Japan for individuals ages 3- to less than 8-years-old, who do not have any deletions in exon 8 and/or exon 9 in the Duchenne gene and who are negative for anti-AAVrh74 antibodies."
10-Q 2025-08-06 125 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, small interfering RNA ("siRNA") platform, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-(“AAV”) based gene therapy, was approved by the FDA on June 20, 2024 for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene, as well as for non-ambulatory patients under the accelerated approval pathway."
"In June 2025, the Company received a milestone payment of $ 63.5 million in connection with the receipt of regulatory approval of ELEVIDYS in Japan for individuals ages 3- to less than 8-years-old, who do not have any deletions in exon 8 and/or exon 9 in the Duchenne gene and who are negative for anti-AAVrh74 antibodies."
10-Q 2025-05-06 116 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-(“AAV”) based gene therapy, was approved by the FDA on June 20, 2024 for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene, as well as for non-ambulatory patients under the accelerated approval pathway."
"Contract manufacturing revenue and royalty revenue are included in collaboration and other revenues in the unaudited condensed consolidated statements of comprehensive (loss) income."
10-K 2025-02-28 159 keyword mentions
"• our expectation that our partnerships with manufacturers will support our clinical and commercial manufacturing capacity for our Duchenne muscular dystrophy (“Duchenne”) gene therapy program and Limb-girdle muscular dystrophy (“LGMD”) programs, while also acting as a manufacturing platform for potential future gene therapy programs, and our belief that our current network of manufacturing partners is able to fulfill the requirements of our commercial plan;"
"(“Catalent”) will support our clinical and commercial manufacturing demand for our Duchenne gene therapy program and LGMD programs, while also acting as a manufacturing platform for potential future gene therapy programs;"
"• our expectation that Aldevron LLC (“Aldevron”) will provide Good Manufacturing Processes (“GMP”)-grade plasmid for our Duchenne gene therapy program and LGMD programs, as well as plasmid source material for future gene therapy programs;"
10-Q 2024-11-06 120 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-(“AAV”) based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene."
"Contract manufacturing revenue and royalty revenue are included in collaboration and other revenue in the accompanying unaudited condensed consolidated statements of comprehensive income (loss)."
10-Q 2024-08-07 118 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients at least 4 years old with Duchenne with a confirmed mutation in the Duchenne gene."
"For the six months ended June 30, 2024, the Company recognized $ 5.8 million of contract manufacturing revenue related to these shipments, with no similar activity for the six months ended June 30, 2023."
10-Q 2024-05-01 108 keyword mentions
"(together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases."
"For the three months ended March 31, 2024, the Company recognized $ 5.8 million of contract manufacturing revenue related to these shipments, with no similar activity for the three months ended March 31, 2023."
"Accrued contract manufacturing costs"
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Codiak BioSciences (Sarepta)

How many clinical programs is Codiak BioSciences (Sarepta) linked to?
Codiak BioSciences (Sarepta) is associated with 16 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Codiak BioSciences (Sarepta)'s CDMO Signal Score?
Codiak BioSciences (Sarepta) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Codiak BioSciences (Sarepta) for a manufacturing program?
Use the free AI matchmaker to compare Codiak BioSciences (Sarepta) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Exosome CDMOs →

Similar CDMOs

Esco Aster
Singapore, Singapore
Signal Score: 63.0
Cell Therapy, Exosome
ExoXpert (EXO Biologics)
Liège, Belgium
Signal Score: 56.5
Exosome
Evox Therapeutics
Oxford, United Kingdom
Signal Score: 56.5
Exosome
Exopharm
Melbourne, Australia
Signal Score: 56.5
Exosome
Clara Biotech
Indianapolis, IN
Signal Score: 56.5
Exosome

Compare Codiak BioSciences (Sarepta) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Codiak BioSciences (Sarepta)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.